Conivaptan: A step forward in the treatment of hyponatremia?

Therapeutics and Clinical Risk Management

Volumn 4, Issue 2, 2008, Pages 315-326

  Hline, Su Su ^a   Pham, Phuong Truc T ^b   Pham, Phuong Thu T ^c   Aung, May H ^a   Pham, Phuong Mai T ^d   Pham, Phuong Chi T ^a  

^a OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

AVP; AVP receptor antagonist; Conivaptan; Euvolemia; Hypervolemia; Hyponatremia

Indexed keywords

ALCOHOL; AMLODIPINE; ARGIPRESSIN; CLARITHROMYCIN; CONIVAPTAN; DEMECLOCYCLINE; DIGOXIN; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LITHIUM SALT; LIXIVAPTAN; LOOP DIURETIC AGENT; MIDAZOLAM; PLACEBO; SATAVAPTAN; SIMVASTATIN; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ACUTE KIDNEY TUBULE NECROSIS; AREA UNDER THE CURVE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DIET SUPPLEMENTATION; DOSE TIME EFFECT RELATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; FEVER; HEADACHE; HEART ARRHYTHMIA; HEMODYNAMIC PARAMETERS; HOMEOSTASIS; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOVOLEMIA; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY POLYCYSTIC DISEASE; LIVER CIRRHOSIS; LOADING DRUG DOSE; LONG TERM EXPOSURE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEPHROGENIC DIABETES INSIPIDUS; PHLEBITIS; PHOTOSENSITIVITY; POLYDIPSIA; REVIEW; RISK BENEFIT ANALYSIS; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; THIRST; UREMIA; VASOPRESSIN RELEASE; WATER DEPRIVATION;

EID: 44049094699     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Adrogué HJ, Madias NE. 2000. Hyponatremia. N Engl J Med, 342:1581-9.
2. Andreoli TE. 2000. Water: Normal balance, hyponatremia, and hypernatremia. Ren Fail, 22:711-35.
3. Arieff AL, Llach F, Massry SG. 1976. Neurological manifestations and morbidity of hyponatremia: Correlation with brain water and electrolytes. Medicine (Baltimore), 55:121-9.
4. Astellas Pharma US, Inc: 2007. Vaprisol (conivaptan hydrochloride injection) product monograph. Deerfield, IL.
5. Bartter FC, Schwartz WB. 1967. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med, 42:790-806.
6. Baylis PH. 1989. Regulation of vasopressin secretion. Baillieres Clin Endocrinol Metab, 3:313-30.
7. Baylis PH. 2003. The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol, 35:1495-9.
8. Bennani SL, Abouqal R, Zeggwagh AA, et al. 2003. Incidence, causes and prognostic factors of hyponatremia in intensive care. Rev Med Interne, 24:224-9.
9. Berl T. 2007. Treatment of the syndrome of inappropriate antidiuretic hormone secretion and the emergence of vasopressin antagonists for hyponatremic disorders. [online]. May 2007. URL: http://www.nephrologyrounds.org
10. Bernier V, Morello JP, Zarruk A, et al. 2006. Pharmacologic Chaperones as a Potential Treatment for X-Linked Nephrogenic Diabetes Insipidus. J Am Soc Nephrol, 17:232-43.
11. Borroni G, Maggi A, Sangiovanni A, et al. 2000. Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. Dig Liver Dis, 32:605-10.
12. Burnier M, Fricker AF, Hayoz, D, et al. 1999. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol, 55:633-7.
13. Cardenas A, Arroyo V. 2003. Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites. Best Pract Res Clin Endocrinol Metab, 17:607-22.
14. Davison JM, Vallotton MB, Lindheimer MD. 1981. Plasma osmolality and urinary concentration and dilution during and after pregnancy: Evidence that lateral recumbency inhibits maximal urinary concentrating ability. Br J Obstet Gynaecol, 88:472-9.
15. DeVita MV, Gardenswartz MH, Konecky A, et al. 1990. Incidence and etiology of hyponatremia in an intensive care unit. Clin Nephrol, 34:163-6.
16. Dunn FL, Brennan TJ, Nelson AE, et al. 1973. The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J Clin Invest, 52:3212-9.
17. Fraser CL, Arieff AI. 1997. Epidemiology, pathophysiology, and management of hyponatremic encephalopathy. Am J Med, 102:67-77.
18. Fried LF, Palevsky PM. Hyponatremia and hypernatremia. 1997. Med Clin North Am, 81:585-609.
19. Fujiwara TM, Bichet DG. 2005. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol, 16:2836-46.
20. Gattone VH, Wang X, Harris PC, et al. 2003. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med, 9:1323-6.
21. Gerbes AL, Gulberg V, Gines P, et al. 2003. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: Arandomized double-blind multicenter trial. Gastroenterology, 124:933-9.
22. Ghali JK, Koren MJ, Taylor JF, et al. 2006. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab, 91:2145-52.
23. Ghali JK, Smith N. 2004. Efficacy of the vasopressin V1A/V2 antagonist conivaptan in patients with euvolemic or hypervolemic hyponatremia. J Am Soc Nephrol, 15:355A. (abstr SA-P0251).
24. Gheorghiade M, Gattis WA, O'Connor CM, et al. 2004. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA, 291:1963-71.
25. Gheorghiade M, Niazi I, Ouyang J, et al. 2003. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind, randomized trial. Circulation, 107:2690-6.
26. Goldberg A, Hammerman H, Petcherski S, et al. 2004. Prognostic importance of hyponatremia in acute ST-elevation myocardial infarction. Am J Med, 117:242-8.
27. Gross P, Bisaha JG, Smith N. 2004. Conivaptan, a novel V1A and V2 antagonist, increased serum sodium and effective water clearance in patients with euvolemic or hypervolemic hyponatremia. J Am Soc Nephrol, 15:355A. (abstr SA-P0243).
28. Hew-Butler T, Almond C, Ayus C, et al. 2005. Exercise-Associated Hyponatremia (EAH) Consensus Panel. Clin J Sport Med, 15:208-13.
29. Ishikawa SE, Schrier RW 2003. Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol, 58:1-17.
30. Landwehr M, Huling U. 2007. Study shows vaprisol® is effective in increasing serum sodium levels and well-tolerated in patients with euvolemic or hypervolemic hyponatremia. Astella News Release, www.astellas.us/press_room/docs
31. Lee CR, Watkins ML, Patterson JH, et al. 2003. Vasopressin: A new target for the treatment of heart failure. Am Heart J, 146:9-18.
32. Lee CT, Guo HR, Chen JB. 2000. Hyponatremia in the emergency department. Am J Emerg Med, 18:264-8.
33. Markowitz GS, Radhakrishnan J, Kambham N, et al. 2000. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol, 11:1439-48.
34. Miller PD, Linas SL, Schrier RW. 1980. Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. JAMA, 243:2513-5.
35. Pham PC, Pham PM, Pham PT. 2006. Vasopressin excess and hyponatremia. Am J Kidney Dis, 47:727-37.
36. Robben JH, Knoers NV, Deen PM. 2006. Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus. Am J Physiol Renal Physiol, 291:F257-70.
37. Robertson GL. 1987. Physiology of ADH Secretion. Kidney Int, Suppl 21:S20-6.
38. Robinson AG, Roberts MM, Evron WA, et al. 1990. Hyponatremia in rats induces downregulation of vasopressin synthesis. J Clin Invest, 86:1023-9.
39. Rouleau J-L, Packer M, Moye L, et al. 1994. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol, 24:583-91.
40. Ruf AE, Kremers WK, Chavez LL, et al. 2005. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl, 11:336-43.
41. Sedlacek M, Schoolwerth AC, Remillard BD. 2006. Electrolyte disturbances in the intensive care unit. Semin Dial, 19:496-501.
42. Serradeil-Le Gal C, Wagnon J, Valette G, et al. 2002. Nonpeptide vasopressin receptor antagonists: Development of selective and orally active V1A, V2 and V1B receptor ligands. Prog Brain Res, 139:197-210.
43. Singer I, Rotenberg D. 1973. Demeclocycline-induced nephrogenic disbetes insipidus. In vivo and in vitro studies. Ann Intern Med, 79:679-83.
44. Sladek CD. 1983. Regulation of vasopressin release by neurotransmitters, neuropeptides and osmotic stimuli. Prog Brain Res, 60:71-90.
45. Soupart A, Gross P, Legros J-J, et al. 2006. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol, 1:1154-60.
46. Terzian C, Frye EB, Piotrowski ZH. 1994. Admission hyponatremia in the elderly: Factors influencing prognosis. J Gen Intern Med, 9:89-91.
47. Thibonnier M, Coles P, Thibonnier A, et al. 2001. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol, 41:175-202.
48. Torres VE, Harris PC. 2006. Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol, 2:40-55.
49. Torres VE, Wang X, Qian Q, et al. 2004. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med, 10:363-4.
50. Udelson JE, Smith WB, Hendrix GH, et al. 2001. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation, 104:2417-23.
51. Verbalis JG, Bisaha JG, Smith N. 2004. Novel vasopressin V1A and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia. J Am Soc Nephrol, 15:356A. (abstr SA-P0254).
52. Verbalis JG. 2003. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab, 17:471-503.
53. [VHA] VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel. 2006. National PBM Drug Monograph: Conivaptan Hydrochloride Injection (Vaprisol®).
54. Wong F, Blei AT, Blendis LM, et al. 2003. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trial. Hepatology, 37:182-91.
55. Zerbe R, Stropes L, Robertson G. 1980. Vasopressin function in the syndrome of inappropriate antidiuresis. Annu Rev Med, 31:315-27.